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In a retrospective study the association of the production of extracellular DNA (eDNA) in biofilms of clinical staphylococcal
isolates from 60 patients with prosthetic joint infection (PJI) and the clinical outcome were investigated. Data from a previous
study on eDNA production determined in 24-hour biofilms of staphylococcal isolates (Staphylococcus aureus n=30, Staphylococcus
epidermidis n=30) was correlated with the patients’ clinical outcome after 3 and 12 months. Statistical analysis was performed using
either the Spearman’s rank correlations test or the t-test. eDNA production of S. epidermidis in 24-hour biofilms correlatedwith the
patients’ outcome ‘not cured‘ after 12 months. For S. aureus no such correlation was detected.Thus, eDNAmay be a virulence factor
of S. epidermidis. Quantification of eDNA production as a surrogate marker for biofilm formation might be a potential predictive
marker for the management of PJI.
1. Introduction
Periprosthetic joint infections (PJI) are most challenging
complications of orthopedic implant surgery. With the
rapidly increasing number of implanted prostheses, the
impact of PJI is steadily increasing. The relative incidence
ranges between 2% and 2.4% of total hip (THA) and total
knee arthroplasties (TKA) [1]. The pathogenesis of PJI is
associated with the formation of bacterial biofilms involving
the tissue around the implant and implant surfaces. Biofilm
formation is a bacterial strategy to survive under adverse
conditions [2]. The production of extracellular polymeric
substances (EPS) protects bacteria against environmental
damage. Moreover, bacteria coated by EPS are also able to
escape the innate immune response [3]. Generally, biofilms
with EPS production enable exchange of genes between
the tightly packed bacterial cells. Moreover, their altered
metabolic state leads to resistance to antibiotics and con-
sequently persistence of infection and treatment failure [4].
About two-thirds of implant-associated infections in ortho-
pedic surgery are caused by two staphylococcal species: S.
aureus and S. epidermidis [5].
Staphylococci have different mechanisms to form bio-
films, which depend on environmental conditions. The most
common pathway used by S. epidermidis is the production
of polysaccharide intercellular adhesin (PIA). PIA is actively
induced through stress conditions, such as, e.g., shear flow,
and heat, and enhances EPS production [6]. When bacteria
were previously exposed to antibiotics, increased production
of extracellular DNA (eDNA) was shown to enhance the
physical properties of EPS and biofilms resistance to antibi-
otics [7, 8]. eDNA is released either by active secretion or
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by cell autolysis and was shown to be linked to the ability of
bacteria to take up DNA from the environment. This feature
called competence contributes to the strategy to survive in the
environment. [9].Theproduction of eDNA is regulated by the
bacterial population density in response to the accumulation
of quorum sensing signals of the closely packed bacterial cells
[10]. eDNA binds with other biofilm polymers (i.e., polysac-
charides and proteins), thus securing structural stability of
the biofilm, and favors bacterial adhesion to abiotic surfaces
[11]. Targeting eDNA might be a strategy for the treatment
of implant-associated infections and other biofilm associated
infections [7, 12, 13].
In a previous study, the time course of eDNA production
in biofilms of clinical isolates of S. aureus and S. epidermidis
was studied. The amount of eDNA (mean % area eDNA)
was visualized and quantified using confocal laser scanning
microscopy (CLSM) and TOTO-1 staining. Image J soft-
ware was used to score the images of stained biofilms.
eDNA production was greater in clinical isolates of S.
epidermidis and S. aureus isolated from PJI compared to
eDNA production of control isolates from the skin of healthy
volunteers. After 24 hours, the amount of eDNA was greater
in biofilms of S. epidermidis than in biofilms of S. aureus.
The production of eDNA varies extensively during the time
course of biofilm development, as well as the respective
staphylococcal species [14].
The aim of the present study was to retrospectively
investigate a possible association of eDNA production of in
vitro biofilms of S. aureus and S. epidermidis clinical isolates
from patients with PJI and the outcome of the treatment of
PJI. The clinical outcomes after 3 and 12 months and the
amount of eDNA production of the respective staphylococcal
isolates in 24-hour biofilms were correlated. Additionally
other influencing parameters like age, weight, the Charlson
index for comorbidity (CCI), the site of the infection, and
laboratory infection parameters including C-reactive protein,
fibrinogen, and leukocyte count were studied.
2. Material and Methods
2.1. Study Design. The study population of this retrospective
study was a previous study population whose pathogens, 60
clinical S. aureus, and S. epidermidis isolates from infected
hip and knee prosthesis were examined for eDNAproduction
[14].
The ethics committee of theMedical University of Vienna
Austria approved the study protocol (Ethic committee no.:
19025).
2.2. Patient Characteristics. Patients’ data were retrospec-
tively retrieved from the electronic patient records. Informa-
tion was collected and anonymously processed using the Uni-
versity of Vienna Research documentation and analysis plat-
form (RDA, research documentation, and analysis). Patients’
characteristics included age, weight, and body-mass-index
(BMI). Comorbidities were collected and categorized using
the Charlson Comorbidity Index; (Comorbidity-Adjusted
Life Expectancy, CCI) [15] (Table 1). Implant indwelling time
was also collected and infection classification (Table 2) was
Table 1: Patient’s demographic data and health index.
Patients description n=60
Age





underweight (< 19) 2 (3,3%)
Normal (19 - < 25) 19 (31%)
overweight (25 - < 30) 24 (40%)




2 19 (31,7 %)
3 5 (8,3 %)





Table 2: Characteristics of implant infect classification with regard
to bacterial species or explanted joint.
Microorganism Joint
S. aureus S. epidermidis hip knee
n = 30 n = 30 n = 29 n = 31
Implant
classification
primary 23 (76.7 %) 13 (43.3%) 16 (53.3 %) 20 (66.7 %)
secondary
(>2) 7 (23.3 %) 17 (56.7%) 14 (46.7 %) 10 (33.3 %)
Infect
classification
early 12 (40 %) - 5 (16.7 %) 7 (22.6 %)
late 18 (60 %) - 11 (36.7 %) 8 (26.7 %)
chronic - 30 (100%) 14 (46.7 %) 15 (50 %)
performed accordingly. Additionally inflammatory markers
such as C-reactive protein (CRP), fibrinogen, and number of
leucocytes were assessed at the time of diagnosis of PJI and
three weeks thereafter.
The clinical outcomes after 3 and 12 months were defined
as (1) cured if patients were able to walk, no further antibiotic
treatment and pain medication were needed and neither
local nor systemic signs of infection were present, (2) not
cured, if patients continued taking antibiotics in order to cure
or suppress infection or were planned for another revision
surgery, or (3) deceased (Table 3). PJI were classified into
early (onset < 1 month after implantation surgery), delayed
(onset 3-24 months after surgery), or late infections (onset >
24 months after surgery) [16].
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Table 3: Outcome classified with regard to bacterial species or
explanted joint type.
Microorganism Joint
S. aureus S. epidermidis hip knee
Outcome after
3 months n=25 n=28 n=23 n=30
cured 16 (64%) 22 (79%) 17 (74%) 21 (70%)
not cured 6 (24%) 5 (18%) 3 (13%) 8 (27%)
dead 3 (12%) 1 (4%) 3 (13%) 1 (3%)
Outcome after
12 months n=21 n=27 n=21 n=27
cured 18 (86%) 22 (81%) 18 (86%) 22 (81%)
not cured 3 (14%) 4 (15%) 2 (10%) 5 (19%)
dead 0 (0%) 1 (4%) 1 (5%) 0 (0%)
2.3. Antimicrobial Susceptibility. Antimicrobial susceptibility
testing to cefoxitin, gentamicin, erythromycin, clindamycin,
fusidic acid, tetracycline, fosfomycin, trimethoprim, line-
zolid, mupirocin, and tigecycline was performed in all
staphylococcal isolates [14] using disc diffusion tests ac-
cording to the protocols of European Committee on Anti-
microbial Susceptibility Testing (EUCAST) (http://www
.eucast.org/clinical breakpoints/).
The multiple antibiotic resistance (MAR) index was
calculated for all tested isolates according to the expression
[17]
MAR = a
(b ∗ c) (1)
where “a” is the aggregate antibiotic resistance score of all
isolates, “b” is the number of antibiotics, and “c” is the
number of isolates. The MAR of all tested isolates was 0,183.
According to [18] a MAR index of 0.183 indicates that the
aggregate antibiotic resistance is low; i.e., the isolates were in
general susceptible to the tested antibiotics.
2.4. Statistical Methods. Spearman's rank correlation and the
t-test were used to assess parallels in eDNA production,
antibiotic resistance, patients clinical conditions, and out-
comes. A p-value of <0.05 was considered to be statistically
significant. eDNA values were log-transformed and checked
for normal distribution before applying the t-test to calculate
the approximate log-normal distribution. Calculations were
performed using IBM-SPSS Version 24.0 (IBM Corp.
Armonk. NY. USA).
3. Results
Sixty patients (27 male, 33 female) with a mean age of 69 year
(range 17-89,median 71) were included into the study.The two
age outliers, 17 and 20 year old patients, suffered fromEwing’s
sarcoma- or osteosarcoma and received total replacements of
the femur and the knee. Thirty-eight of 60 (63.3%) patients
were classified as overweight or obese with a BMI > 25 kg/m2:
24/60 (40%) patients were overweight and 14/60 (23.33%)


















Patients (n=27) outcome aer 12 months
Figure 1: eDNA production in 24h biofilms of S. epidermidis is
greater in isolates of patients with adverse outcome than in patients
with favourable outcome.
patients was classified as cured, and the outcome in 8 patients
was classified as not cured including a patient who died from
the infection. A more detailed description of the outcomes
with regard to pathogens or type of prosthesis is given in
Table 3. A PJI considered as chronic infections were caused
by S. epidermidis.Early or acute late infections were caused by
S. aureus (Table 2). Twelve patients were lost during follow-
up: 8 patients due to incomplete datasets and 4 patients died
from their comorbidities or other age-related diseases (57-84
years; median 75 years old) during the observation period.
3.1. eDNAProduction and ClinicalOutcome. Therewas a cor-
relation between the amount of eDNA in 24 h S. epidermidis
biofilms and patients outcome ‘not cured or respectively
dead’ after 12 months (n=27, r=0.391. p=0.044) but not for S.
aureus (Table 4, Figure 1). For all isolates fromhip prostheses,
there was a positive correlation between eDNA production
and the patients outcome “not cured or respectively dead”
after 12 months (n=21, r=0.605, and p=0.004) (Table 4).
Charlson comorbidity index (CCI) showedno correlation
to eDNA production of 24 hours biofilms.
3.2. eDNA Production and Antimicrobial Susceptibility.
Among 30 clinical S. epidermidis isolates, 16 weremethicillin-
resistant Staphylococcus epidermidis (MRSE) and 9 and
15 showed resistance to rifampicin and clindamycin,
respectively. Eleven out of 30 clinical S. epidermidis isolates
were resistant to fusidic acid. Among 30 clinical S. aureus
isolates, 8 were methicillin-resistant S. aureus (MRSA) and
1 and 5 showed resistance to rifampicin and clindamycin,
respectively. One out of 30 clinical S. aureus isolates
was resistant to fusidic acid. A significantly lower eDNA
production was only found in isolates resistant to fusidic
acid: 4,86 for susceptible isolates versus 2,14 for resistant
isolates [(eDNA 24hmean (% area), n=60, t=5.102, p<=0.001]
and rifampicin: 4,76 for susceptible isolates versus 2,4 for
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Table 4: eDNA production after 24 h in correlation to outcomes after 3 and 12 months with regard to bacterial species or explanted joint.
S. aureus S. epidermidis Hip isolates Knee isolates
eDNA 24log eDNA 24log eDNA24log eDNA24log
Outcome after
3 months n=25 n=28 n=23 n=30
Correlation
Coefficient -0.028 -0.161 -0.293 -0.013
Sig. (2-tailed) 0.894 0.413 0.175 0.945
Outcome after
12 months n=21 n=27 n=21 n=27
Correlation
Coefficient -0.022 0.391 0.605 -0.018
Sig. (2-tailed) 0.923 0.044∗ 0.004∗∗ 0.928
resistant isolates [eDNA 24h mean (% area); n=60, t= 2.257,
and p=0.028)].
3.3. Laboratory Parameters. The analysis of serum inflam-
mation biomarkers revealed that all patients with S. aureus
infections had greater mean serum levels of C-reactive
protein (10.16 ± 3.33 mg/l/day; mean ± standard deviation)
than patients with S. epidermidis infections (5.64 ± 2.14
mg/l/day) (p<0.001) during their 3 weeks clinical follow-
up after surgery. Similarly mean fibrinogen levels were sig-
nificantly greater in patients with PJI caused by S. aureus
551.46 ± 52.51mg/l−1/day) than patients with PJI caused by S.
epidermidis (457.74 (± 80.69 mg/l−1 /day) (p<0.001).
4. Discussion
The increasing life expectancy together with the constant
progress in medicine increases the number of patients
receiving medical implants, e.g., knee and hip prostheses,
pacemakers, or many other medical implants and devices
[19]. Therefore medical implant related infections are an
increasingly substantial burden to the healthcare system
[20, 21]. According to the surveillance of the European
Centers for Disease Prevention and Control (ECDC) the
incidence of surgical site infections (SSIs) after hip and knee
surgery was 1.1%, (ranging from 0.3% to 3.8%) for THA and
0.6% (range 0.0% to 3.4%) for TKA. http://ecdc.europa.eu/
en/healthtopics/Healthcare-associated infections/surgical-site-.
infections/Pages/Annual-epidemiological-report-2016.aspx
In order to treat these infections a thorough understanding
of the pathogenesis and the pathogens is pivotal.Clinical
outcomes of PJI with respect to their causing pathogen and
respective biofilm formation ability are subject of a few stud-
ies only. A prospective study in 124 patients with orthopedic
implant-related osteomyelitis showed the influence of biofilm
formation and antibiotic resistance on the outcome. In the
subgroup of 90 patients with lower extremity infections
the increase of S. epidermidis biofilm thickness correlated
with decreased cure rates [18]. Mittag et al. examined
clinical outcomes after infected knee and hip arthroplasty
using clinical data of 64 patients and scores including the
Western Ontario and McMaster Universities- (WOMAC-)
Index, the Harris Hip Score (HHS) and the Hospital for
Special Surgery Score (HSS). They did not demonstrate a
correlation between implant infection classified according
to the modified Tsukayama classification system [22] and
outcome defined using WOMAC, HSS or HHS score [23].
However, in this study, the most frequent pathogens were
Enterococcus spp. followed by a mixture of bacteria causing
polymicrobial infections
So far a correlation between eDNAproduction in staphyl-
ococcal biofilms and clinical outcome of PJI has not been
reported in the literature. In the present study S. epider-
midis isolates showed significantly greater eDNA production
than S. aureus isolates in the respective 24h biofilms [14].
Infections of S. aureus and S. epidermidis are considered
distinguishable by their clinical symptoms and course: S.
aureus infections usually present with classical local signs
and symptoms of infection with pain, redness, swelling,
temperature and impaired function and a systemic immune
response with fever, hypotension, etc., leucocytosis and ele-
vated C-reactive protein, etc... Infection caused by S. epider-
midis presents usually with subacute signs and symptoms
of infection and an unspecific and delayed onset. In the
present patient population infections with S. epidermidis
presented as chronic infections. Early or late acute infections
were exclusively caused by S. aureus (Table 2).We were able
to demonstrate that eDNA production of S. epidermidis 24
hours biofilms correlated with the clinical outcome ‘not
cured respectively dead’ after 12 months, (p=0.044). eDNA
production is a relatively stable characteristic of many S.
epidermidis strains [14]. Thus, it may be hypothesized that
production of eDNA by S. epidermidis isolated from PJI
contributes to the pathogenesis and may be used to predict
clinical outcome.
Exposure to antibiotics has been linked to eDNA produc-
tion in biofilms [24, 25]. Perioperative antibiotic prophylaxis
is a standard of care in orthopaedic prosthetic surgery
[26]. However, Doroshenko et al. reported higher eDNA
levels in biofilms of S. epidermidis after prior exposure to
vancomycin [25]. Schilcher et al. described that subinhibitory
concentrations of clindamycin increased the ability of S.
aureus to form biofilms and shift the composition of the
biofilm matrix towards higher eDNA content [27]. In the
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present study, isolates resistant to rifampicin and fucidic acid
produced less amounts of eDNA than susceptible ones. But,
antimicrobial resistance was tested only using the disk diffu-
sion method testing planktonic bacteria compared to biofilm
susceptibility testing performed in the other studies [27]
or as demonstrated by Brady and colleagues in their study
comparing minimum biofilm eradication concentration and
minimum inhibitory concentration breakpoint in planktonic
versus biofilm grown staphylococci [28]. However, further
investigation into the effects of rifampicin or fusidic acid
on eDNA production should be done performing resistance
testing in biofilm growth systems.
Inflammation biomarkers such as fibrinogen, C-reactive
protein, and leucocyte count did not correlate with eDNA
levels of 24 hours biofilms of the respective pathogens. Yet,
a significant difference between the clinical presentation of
PJI caused by either S. aureus or S. epidermidis was found
in our patient population likewise in earlier studies [29, 30],
where patients with PJI caused by S. aureus exhibited greater
serum levels of C-reactive protein and fibrinogen compared
to patients with PJI caused by S. epidermidis.
The limitations of the present study are inherent to the
retrospective nature of the study because not all clinical and
laboratory data are available, and there is a rather small sam-
ple size of a nevertheless very well defined patient population.
Due to the small sample size, multivariate statistical analysis
was not indicated. Moreover, in vitro conditions of biofilm
formation may not fully reflect clinical biofilms in PJI [31].
5. Conclusion
In conclusion, a correlation between increased eDNA pro-
duction of S. epidermidis 24h biofilms and adverse clinical
outcome after 12monthswas demonstrated.Quantification of
eDNA production of the pathogen as a surrogate marker for
biofilm formation might be a potential predictive marker for
themanagement of PJI caused by S. epidermidis. eDNAmight
also be a possible therapeutic target. Further prospective
and sufficiently powered clinical studies will be needed to
strengthen the role of eDNA production of pathogens on the
clinical course and its relevance in PJI.
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